BioProcessors' SimCell Platform Demonstrates Potential to Increase Amgen's Cell Culture Experiment Capacity - PRWeb Press Release Group http://www.rsspad.com/rss2/4913.xml BioProcessors, biochemical, Amgen, AMGN, SimCell, MicroBioreactor, mammalian cell culture, process development, arrays, scale-down, fed batch cell culture processes, high-throughput, process development, biotechnology, pharmaceutical, cell culture, experiment capacity, data quality, faster cycles, costs, biopharmaceutical, processing method, well plate, shake flask, cell line selection, process optimization, bioreactor, full factorial process development, global optima, microfluidics, manufacturing processes, experiments, MicroBioreactors , scalability, SimCells, scale-up, candidate drugs, production, fermentation yields, experiment data, multi-factorial design, full DOE, drugs, cell growth, SimCell Automation and Management System, oxygen, temperature, pH, cell culture, SimCell Insight, SimCell KnowledgeSource, KnowledgeSource, Novo Nordisk, NYSE: NVO, drug production processes, HighGround. - Powered by PRWeb and RSSPad en xml@emediawire.com xml@emediawire.com 30 BioProcessors’ SimCell Platform Selected by Novo Nordisk: Company Chooses SimCell MicroBioreactor System For High-Throughput Mammalian Cell Culture Process Development http://www.prweb.com/releases/2005/09/prweb285427.htm Pharmaceutical giant Novo Nordisk purchases BioProcessors' MicroBioreactor Automation Management System, Proves Critical to the Success of Novo Nordisk’s Biologics Programs (PRWeb Sep 15, 2005)

Read the full story at http://www.prweb.com/releases/2005/09/prweb285427.htm

]]> Thu, 15 Sep 2005 07:00:00 GMThttp://www.prweb.com/releases/2005/09/prweb285427.htm BioProcessors’ SimCell Platform Demonstrates Potential to Increase Amgen’s Cell Culture Experiment Capacity http://www.prweb.com/releases/2005/07/prweb261163.htm BioProcessors is presenting the results of its relationship that relates to the press release at an industry session this week that will ultimately impact the pharma and biotech markets on a business and scientific level. Results to be Presented in Poster Session at Biochemical Engineering XIV Show Release summary: Until now, there was the problem of poor scalability and, in the case of shake flasks, insufficient experimental power to provide complete full factorial process development DOEs limits researchers real-time ability to identify robust processes capable of operating at their global optima. BioProcessors has solved this. Read entire release for details. (PRWeb Jul 13, 2005)

Read the full story at http://www.prweb.com/releases/2005/07/prweb261163.htm

]]> Wed, 13 Jul 2005 07:00:00 GMThttp://www.prweb.com/releases/2005/07/prweb261163.htm